Morgan Stanley has a team of investors and researchers tasked with identifying the next “big idea that has the potential to trigger far-reaching consequences.” The team, operating under the name Counterpoint Global, has now profiled psychedelics in a four-page viewpoint piece ( PDF). Operating under the Morgan Stanley Investment Management (MSIM) banner, Counterpoint is a fundamental equity team…
